This may result in chromosomal instability and serve as a tumor susceptibility locus.[2] Several studies revealed that TRIP13 can drive tumorigenesis and promote tumor progress, leading to a poor prognosis for individuals with prostate cancer,[4] bladder cancer,[5] B-cell lymphoma, and multiple myeloma.[6] A thorough examination of the role of TRIP13 in tumor occurrence and progression, along with an investigation of its potential carcinogenic mechanisms, is crucial for identifying potential therapeutic targets for various cancers. Here, TRIP13 is linked to plasma cell myeloma.